Conclusions, Induced pluripotent stem cells represent a promising new field where it may offer novel treatments for current unmet medical needs. However, the iPSC field also pose several technical challenges that are absent with traditional small and large molecules. Before iPSC-derived cell replacement therapies can be realized, several scientific, financial, manufacturing and regulatory challenges will ultimately need to be addressed. Those challenges include addressing genetic stability and cell heterogeneity, creating processes that improve cell safety, establishing manufacturing workflows that maintain cell reproducibility through the entire scale-up process, and implementing quality controls that characterize and predict cell potency. These milestones will be arduous to achieve. Yet, it is hopeful with persistence this field will finally deliver products that offer hope to patients who suffer from chronic disease.
CYP Price at posting:
24.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)